A Study to Collect Data About Analgesia in Patients With Bone Metastasis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2017-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Up to 180 patients with bone metastasis and requiring analgesic treatment will be followed during 4 to 10 weeks. All patients will continue to receive their cancer therapeutic treatments and be treated for pain relief exactly as they would normally be by the Investigator based on their needs. During their regular visits to the Investigator, patients will complete questionnaires and Clinical Pain Assessments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Factors of Analgesic Response in Patients With Pain Associated With Bone Metastasys

NCT06777004

Cancer Pain

COMPLETED

Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer

NCT00712712

Metastatic Cancer Pain Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE2

Individualized Pharmaceutical-care for Inpatients With Cancer Pain

NCT03455023

Cancer Pain

UNKNOWN NA

Utility of an APP for the Monitoring of Irruptive Oncological Pain

NCT03597737

Oncology Pain, Acute Pain, Chronic

COMPLETED NA

Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms

NCT04491123

Refractory Cancer Pain Intrathecal Analgesia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires completion

Intervention Type OTHER

Clinical Pain Assessments

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with bone tumors or bone metastasis from any primary cancer origin that is supported by histological or radiological investigations.
* Patients having been or being treated for their bone metastasis and/or their primary cancer.
* Patients who require analgesic treatment for unsatisfactory pain relief.
* Patients will be required to score at least 4 on the WAPS 11-point NRS during the week preceding enrollment.
* Patients undergoing or not a radiotherapy program provided visit procedures are performed before any radiotherapy sessions if scheduled on the same visit days.
* Are men or women of at least 18 years of age.
* Are reliable and willing to make themselves available for the entire duration of the study and are willing to follow study procedures.
* Have given written informed consent approved by the relevant Ethics Committee governing the study site.

Exclusion Criteria

* Patients having had a major surgery within 28 days prior to signing Informed Consent Document or planning to have a major surgery during the study.
* Patients having a life expectancy \< 3 months according to Investigator judgment.
* Patients having poor nutritional status or whose condition is unstable or who could be rapidly deteriorating in such a way that they would not be able to complete the study.
* Patients with a current or recent history unrelated to their cancer condition, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study.
* Patients having a Karnofsky performance status below 70% or WHO score (Eastern Cooperative Oncology Group (ECOG)/Zubrod score) above 1.
* Are Investigator site staffs directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
* Any other relevant medical disorder likely to interfere with the trial or represent a risk for the patient.
* Patients under legal protection, according to the country law.
* Patients currently enrolled in a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period according to the national law.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No